content/01.introduction.md:4:Indeedm
content/01.introduction.md:4:NSCLC
content/01.introduction.md:4:supressive
content/01.introduction.md:6:adenocarcinomas
content/01.introduction.md:6:alveoli
content/01.introduction.md:6:BRAF
content/01.introduction.md:6:EGFR
content/01.introduction.md:6:genomic
content/01.introduction.md:6:histological
content/01.introduction.md:6:histological
content/01.introduction.md:6:KRAS
content/01.introduction.md:6:MAPK
content/01.introduction.md:6:NSCLC
content/01.introduction.md:6:NSCLC
content/01.introduction.md:6:SCLC
content/01.introduction.md:6:subtype
content/01.introduction.md:8:metastaized
content/01.introduction.md:10:ALK
content/01.introduction.md:10:autophagy
content/01.introduction.md:10:BRAF
content/01.introduction.md:10:Carboplatin
content/01.introduction.md:10:chemotherapeutics
content/01.introduction.md:10:Cisplatin
content/01.introduction.md:10:EGFR
content/01.introduction.md:10:immunotherapy
content/01.introduction.md:10:immunotherapy
content/01.introduction.md:10:inhibtion
content/01.introduction.md:10:MEK
content/01.introduction.md:10:Paclitaxel
content/01.introduction.md:10:Pemetrexed
content/01.introduction.md:10:ROS
content/01.introduction.md:10:TRK
content/01.introduction.md:12:ARAF
content/01.introduction.md:12:BRAF
content/01.introduction.md:12:BRAF
content/01.introduction.md:12:BRAF
content/01.introduction.md:12:constitutively
content/01.introduction.md:12:CRAF
content/01.introduction.md:12:effciency
content/01.introduction.md:12:EGF
content/01.introduction.md:12:EGF
content/01.introduction.md:12:glutamic
content/01.introduction.md:12:GTP
content/01.introduction.md:12:GTP
content/01.introduction.md:12:GTP
content/01.introduction.md:12:GTP
content/01.introduction.md:12:independet
content/01.introduction.md:12:kinases
content/01.introduction.md:12:kinases
content/01.introduction.md:12:kinases
content/01.introduction.md:12:Kinases
content/01.introduction.md:12:ligand
content/01.introduction.md:12:ligand
content/01.introduction.md:12:ligands
content/01.introduction.md:12:MAPK
content/01.introduction.md:12:MAPK
content/01.introduction.md:12:MAPK
content/01.introduction.md:12:mitogens
content/01.introduction.md:12:NGF
content/01.introduction.md:12:oncogenic
content/01.introduction.md:12:oncogenic
content/01.introduction.md:12:phosphorylates
content/01.introduction.md:12:phosphorylates
content/01.introduction.md:12:RAS
content/01.introduction.md:12:RAS
content/01.introduction.md:12:RAS
content/01.introduction.md:12:RAS
content/01.introduction.md:12:RAS
content/01.introduction.md:12:RAS
content/01.introduction.md:12:RTKs
content/01.introduction.md:12:RTKs
content/01.introduction.md:12:transcriptional
content/01.introduction.md:12:Tyrosine
content/01.introduction.md:12:valine
content/01.introduction.md:14:autophagy
content/01.introduction.md:14:BRAF
content/01.introduction.md:14:BRAF
content/01.introduction.md:14:BRAF
content/01.introduction.md:14:Dabrafenib
content/01.introduction.md:14:kinases
content/01.introduction.md:14:MAPK
content/01.introduction.md:14:MEK
content/01.introduction.md:14:MEK
content/01.introduction.md:14:pre
content/01.introduction.md:14:Trametinib
content/01.introduction.md:17:proto
content/01.introduction.md:19:carinogene
content/01.introduction.md:19:GEMMs
content/01.introduction.md:19:latencies
content/01.introduction.md:19:MNU
content/01.introduction.md:19:pentrance
content/01.introduction.md:19:ressemble
content/01.introduction.md:21:Cre
content/01.introduction.md:21:Cre
content/01.introduction.md:21:doxycycline
content/01.introduction.md:21:inducible
content/01.introduction.md:21:KRAS
content/01.introduction.md:21:LoxP
content/01.introduction.md:21:LoxP
content/01.introduction.md:21:LoxP
content/01.introduction.md:21:polyadenylation
content/01.introduction.md:21:recombinase
content/01.introduction.md:21:transcriptial
content/01.introduction.md:21:transgenes
content/01.introduction.md:23:BRAF
content/01.introduction.md:23:preclinical
content/01.introduction.md:23:transcriptional
content/01.introduction.md:25:adenocarcinomas
content/01.introduction.md:25:BRAF
content/01.introduction.md:25:EGFR
content/01.introduction.md:25:GEMMs
content/01.introduction.md:25:KRAS
content/01.introduction.md:25:MAPK
content/01.introduction.md:27:BRAF
content/01.introduction.md:27:BRAF
content/01.introduction.md:27:BRAF
content/01.introduction.md:27:BRAF
content/01.introduction.md:27:CAAX
content/01.introduction.md:27:cDNA
content/01.introduction.md:27:Cre
content/01.introduction.md:27:Cre
content/01.introduction.md:27:fluorophore
content/01.introduction.md:27:LoxP
content/01.introduction.md:27:LoxP
content/01.introduction.md:27:onco
content/01.introduction.md:27:oncoprotein
content/01.introduction.md:27:TdTomato
content/01.introduction.md:29:adenomas
content/01.introduction.md:29:BRAF
content/01.introduction.md:29:BRAF
content/01.introduction.md:29:BRAF
content/01.introduction.md:29:BRAF
content/01.introduction.md:29:Hanahan
content/01.introduction.md:29:MAPK
content/01.introduction.md:29:oncogenic
content/01.introduction.md:29:overide
content/01.introduction.md:29:pneumocytes
content/01.introduction.md:29:proto
content/01.introduction.md:29:suppresed
content/01.introduction.md:29:Surfactant
content/01.introduction.md:29:Tumorigenesis
content/01.introduction.md:29:WNT
content/01.introduction.md:32:egfr
content/01.introduction.md:32:erk
content/01.introduction.md:32:mek
content/01.introduction.md:32:ras
content/01.introduction.md:34:luad
content/01.introduction.md:34:tumorigenesis
content/01.introduction.md:36:BRAF
content/01.introduction.md:36:gemms
content/01.introduction.md:40:wnt
content/01.introduction.md:44:engagment
content/01.introduction.md:44:evoltionary
content/01.introduction.md:44:supression
content/01.introduction.md:46:antigene
content/01.introduction.md:46:decameric
content/01.introduction.md:46:oligomerization
content/01.introduction.md:46:tetramerization
content/01.introduction.md:46:transactivation
content/01.introduction.md:46:transactivation
content/01.introduction.md:46:transcriptional
content/01.introduction.md:46:transcriptional
content/01.introduction.md:46:transcriptional
content/01.introduction.md:48:Fraumeni
content/01.introduction.md:48:leukemias
content/01.introduction.md:52:phenotypes
content/01.introduction.md:52:stressor
content/01.introduction.md:54:cDNA
content/01.introduction.md:54:ectopic
content/01.introduction.md:54:misclassification
content/01.introduction.md:54:RAS
content/01.introduction.md:56:hemizygosity
content/01.introduction.md:56:hotspot
content/01.introduction.md:56:hotspots
content/01.introduction.md:56:tetramer
content/01.introduction.md:56:transcriptional
content/01.introduction.md:58:chemoresistance
content/01.introduction.md:58:Fraumeni
content/01.introduction.md:58:Fraumeni
content/01.introduction.md:58:GOF
content/01.introduction.md:58:GOF
content/01.introduction.md:58:LOF
content/01.introduction.md:58:LOF
content/01.introduction.md:58:missense
content/01.introduction.md:58:missense
content/01.introduction.md:58:tumorigenic
content/01.introduction.md:60:Catenin
content/01.introduction.md:60:CREB
content/01.introduction.md:60:GOF
content/01.introduction.md:60:KRAS
content/02.tubaseq.md:10:dabrafenib
content/02.tubaseq.md:10:mutationas
content/02.tubaseq.md:10:trametinib
content/02.tubaseq.md:11:BRAF
content/02.tubaseq.md:11:BRAF
content/02.tubaseq.md:11:differentially
content/02.tubaseq.md:11:Identificaton
content/02.tubaseq.md:11:targeed
content/02.tubaseq.md:12:BRAF
content/02.tubaseq.md:12:BRAF
content/02.tubaseq.md:12:BRAF
content/02.tubaseq.md:12:colorectal
content/02.tubaseq.md:12:mealanoma
content/02.tubaseq.md:13:GEMMs
content/02.tubaseq.md:13:pre
content/02.tubaseq.md:15:Genomic
content/02.tubaseq.md:16:histiological
content/02.tubaseq.md:17:tumorigenesis
content/02.tubaseq.md:22:bona
content/02.tubaseq.md:22:fide
content/02.tubaseq.md:22:GEMMs
content/02.tubaseq.md:23:GEMMs
content/02.tubaseq.md:23:scalable
content/02.tubaseq.md:23:suboptimal
content/02.tubaseq.md:25:histological
content/02.tubaseq.md:25:IHC
content/02.tubaseq.md:25:immunohistochemistry
content/02.tubaseq.md:26:acheive
content/02.tubaseq.md:28:mor
content/02.tubaseq.md:28:rcode
content/02.tubaseq.md:28:uencing
content/02.tubaseq.md:28:Winslow
content/02.tubaseq.md:29:barcoded
content/02.tubaseq.md:29:Cre
content/02.tubaseq.md:29:Cre
content/02.tubaseq.md:29:endoing
content/02.tubaseq.md:29:lentiviral
content/02.tubaseq.md:29:recombinase
content/02.tubaseq.md:34:BRAF
content/02.tubaseq.md:34:tumorigenesis
content/02.tubaseq.md:35:adenoma
content/02.tubaseq.md:36:BRAF
content/02.tubaseq.md:36:stromal
content/02.tubaseq.md:37:BRAF
content/02.tubaseq.md:37:CRISPR
content/02.tubaseq.md:37:Therfore
content/02.tubaseq.md:40:acheive
content/02.tubaseq.md:40:Adenoviral
content/02.tubaseq.md:40:GEMMs
content/02.tubaseq.md:40:lentiviral
content/02.tubaseq.md:40:numerosity
content/02.tubaseq.md:40:titrated
content/02.tubaseq.md:41:adenoviruses
content/02.tubaseq.md:41:barcode
content/02.tubaseq.md:41:lentiviral
content/02.tubaseq.md:42:CRISPR
content/02.tubaseq.md:42:lentiviruses
content/02.tubaseq.md:42:oncogenic
content/02.tubaseq.md:43:actvation
content/02.tubaseq.md:43:BRAF
content/02.tubaseq.md:43:LSL
content/02.tubaseq.md:43:supressor
content/02.tubaseq.md:44:barcoded
content/02.tubaseq.md:44:BRAF
content/02.tubaseq.md:44:BRAF
content/02.tubaseq.md:44:Cre
content/02.tubaseq.md:44:lentiviral
content/02.tubaseq.md:44:plasmids
content/02.tubaseq.md:44:recombinase
content/02.tubaseq.md:44:sgRNA
content/02.tubaseq.md:44:tumorigenesis
content/02.tubaseq.md:45:barcoded
content/02.tubaseq.md:45:lentiviral
content/02.tubaseq.md:45:lentiviruses
content/02.tubaseq.md:47:barcode
content/02.tubaseq.md:47:genomic
content/02.tubaseq.md:47:preperation
content/02.tubaseq.md:47:titer
content/02.tubaseq.md:47:titer
content/02.tubaseq.md:48:barcoded
content/02.tubaseq.md:48:genomic
content/02.tubaseq.md:50:BRAF
content/02.tubaseq.md:51:BRAF
content/02.tubaseq.md:53:histologic
content/02.tubaseq.md:54:BRAF
content/02.tubaseq.md:58:BRAF
content/02.tubaseq.md:59:BRAF
content/02.tubaseq.md:59:catenin
content/02.tubaseq.md:59:tumorigenesis
content/02.tubaseq.md:59:Wnt
content/02.tubaseq.md:60:catenin
content/02.tubaseq.md:61:BRAF
content/02.tubaseq.md:61:tumorigenesis
content/02.tubaseq.md:63:BRAF
content/02.tubaseq.md:63:RNAs
content/02.tubaseq.md:65:immunohistochemistry
content/02.tubaseq.md:65:immunohistochemistry
content/02.tubaseq.md:66:BRAF
content/02.tubaseq.md:66:CRISPR
content/02.tubaseq.md:72:MAPK
content/02.tubaseq.md:73:BRAF
content/02.tubaseq.md:73:Oncogenic
content/02.tubaseq.md:74:BRAF
content/02.tubaseq.md:74:tumorigenesis
content/02.tubaseq.md:75:BRAF
content/02.tubaseq.md:75:GEMMs
content/02.tubaseq.md:75:tummor
content/02.tubaseq.md:75:WNT
content/02.tubaseq.md:77:adenoma
content/02.tubaseq.md:77:BRAF
content/02.tubaseq.md:77:stromal
content/02.tubaseq.md:78:adenomas
content/02.tubaseq.md:78:BRAF
content/02.tubaseq.md:79:adenomas
content/02.tubaseq.md:79:BRAF
content/02.tubaseq.md:79:BRAF
content/02.tubaseq.md:79:doublings
content/02.tubaseq.md:79:doublings
content/02.tubaseq.md:79:histological
content/02.tubaseq.md:80:adenomas
content/02.tubaseq.md:80:BRAF
content/02.tubaseq.md:81:absloute
content/02.tubaseq.md:81:BRAF
content/02.tubaseq.md:82:BRAF
content/02.tubaseq.md:82:heterogenous
content/02.tubaseq.md:82:intrinisic
content/02.tubaseq.md:82:reponse
content/02.tubaseq.md:83:fibroblast
content/02.tubaseq.md:83:stromal
content/02.tubaseq.md:83:tumorigenic
content/02.tubaseq.md:84:adenomas
content/02.tubaseq.md:84:BRAF
content/02.tubaseq.md:85:quantifcations
content/02.tubaseq.md:87:BRAF
content/02.tubaseq.md:87:CRISPR
content/02.tubaseq.md:87:sgRNAs
content/02.tubaseq.md:87:supressor
content/02.tubaseq.md:88:adenocarinoma
content/02.tubaseq.md:88:bona
content/02.tubaseq.md:88:fide
content/02.tubaseq.md:89:supressor
content/02.tubaseq.md:89:Wnt
content/02.tubaseq.md:90:BRAF
content/02.tubaseq.md:90:WNT
content/02.tubaseq.md:91:WNT
content/02.tubaseq.md:92:BRAF
content/02.tubaseq.md:94:supressor
content/02.tubaseq.md:95:cBioPortal
content/02.tubaseq.md:96:histone
content/02.tubaseq.md:96:methyltransferase
content/02.tubaseq.md:96:trimethylation
content/02.tubaseq.md:97:trascribed
content/02.tubaseq.md:98:mRNA
content/02.tubaseq.md:98:mRNA
content/02.tubaseq.md:98:TCGA
content/02.tubaseq.md:99:BRAF
content/02.tubaseq.md:100:MAPK
content/02.tubaseq.md:101:transcriptional
content/02.tubaseq.md:102:Feldser's
content/02.tubaseq.md:102:indentified
content/02.tubaseq.md:102:KRAS
content/02.tubaseq.md:102:Similarily
content/02.tubaseq.md:102:tumorigenesis
content/02.tubaseq.md:102:Winslow
content/02.tubaseq.md:103:BRAF
content/02.tubaseq.md:103:KRAS
content/02.tubaseq.md:105:BRAF
content/02.tubaseq.md:105:tumorigenesis
content/02.tubaseq.md:106:KRAS
content/02.tubaseq.md:106:sgRNAs
content/02.tubaseq.md:106:tumorigeneic
content/02.tubaseq.md:109:transcriptional
content/02.tubaseq.md:111:CRISPR
content/02.tubaseq.md:111:ineficient
content/02.tubaseq.md:111:supressor
content/02.tubaseq.md:111:tumorigenesis
content/02.tubaseq.md:113:adenocarcinomas
content/02.tubaseq.md:113:GEMMs
content/02.tubaseq.md:113:tumorigenesis
content/02.tubaseq.md:114:BRAF
content/02.tubaseq.md:114:tumorigenesis
content/02.tubaseq.md:115:adenocarcinomas
content/02.tubaseq.md:116:BRAF
content/02.tubaseq.md:117:BRAF
content/02.tubaseq.md:117:supressors
content/02.tubaseq.md:118:Utltimetly
content/02.tubaseq.md:122:Cre
content/02.tubaseq.md:122:Lenti
content/02.tubaseq.md:122:LSL
content/02.tubaseq.md:122:LSL
content/02.tubaseq.md:122:LSL
content/02.tubaseq.md:122:LSL
content/02.tubaseq.md:122:plasmid
content/02.tubaseq.md:122:sgRNA
content/02.tubaseq.md:122:supressors
content/02.tubaseq.md:124:Jitter
content/02.tubaseq.md:124:LSL
content/02.tubaseq.md:124:LSL
content/02.tubaseq.md:126:identifed
content/02.tubaseq.md:126:Jitter
content/02.tubaseq.md:126:LSL
content/02.tubaseq.md:126:LSL
content/02.tubaseq.md:126:seperated
content/02.tubaseq.md:126:sgID
content/02.tubaseq.md:128:BRAF
content/02.tubaseq.md:128:Cre
content/02.tubaseq.md:128:Cre
content/02.tubaseq.md:128:Lenti
content/02.tubaseq.md:128:Lenti
content/02.tubaseq.md:128:LSL
content/02.tubaseq.md:128:PFU
content/02.tubaseq.md:130:positivty
content/02.tubaseq.md:130:QuantCenter
content/02.tubaseq.md:130:simuletaneously
content/02.tubaseq.md:132:BRAF
content/02.tubaseq.md:132:dataset
content/02.tubaseq.md:132:mRNA
content/02.tubaseq.md:132:mRNA
content/02.tubaseq.md:132:TGCA
content/03.p53.md:5:adenocarcinomas
content/03.p53.md:5:ARF
content/03.p53.md:5:BRAF
content/03.p53.md:5:BRAF
content/03.p53.md:5:BRAF
content/03.p53.md:5:dedifferentiation
content/03.p53.md:5:GEMMs
content/03.p53.md:5:GEMMs
content/03.p53.md:5:homologues
content/03.p53.md:5:hotspot
content/03.p53.md:5:hotspot
content/03.p53.md:5:MEK
content/03.p53.md:5:missense
content/03.p53.md:5:transcriptome
content/03.p53.md:5:vitro
content/03.p53.md:5:vivo
content/03.p53.md:9:BRAF
content/03.p53.md:9:BRAF
content/03.p53.md:9:BRAF
content/03.p53.md:9:EGFR
content/03.p53.md:9:EGFR
content/03.p53.md:9:EGFR
content/03.p53.md:9:GEMMs
content/03.p53.md:9:histologically
content/03.p53.md:9:KRAS
content/03.p53.md:9:KRAS
content/03.p53.md:9:KRAS
content/03.p53.md:9:LUAD
content/03.p53.md:9:LUAD
content/03.p53.md:9:LUAD
content/03.p53.md:9:MAPK
content/03.p53.md:9:MAPK
content/03.p53.md:9:mutationally
content/03.p53.md:9:oncoproteins
content/03.p53.md:9:pneumocyte
content/03.p53.md:9:Siegel
content/03.p53.md:9:transformative
content/03.p53.md:11:ARF
content/03.p53.md:11:chemoresistance
content/03.p53.md:11:genomic
content/03.p53.md:11:LUAD
content/03.p53.md:11:MDMX
content/03.p53.md:11:phenotypes
content/03.p53.md:11:proliferative
content/03.p53.md:11:TGF
content/03.p53.md:11:transcriptional
content/03.p53.md:11:transcriptional
content/03.p53.md:11:transcriptional
content/03.p53.md:13:BRAF
content/03.p53.md:13:BRAF
content/03.p53.md:13:dysregulation
content/03.p53.md:13:GEMMs
content/03.p53.md:13:homologues
content/03.p53.md:13:hotspots
content/03.p53.md:13:phenotypic
content/03.p53.md:13:tumorigenesis
content/03.p53.md:15:BRAF
content/03.p53.md:15:BRAF
content/03.p53.md:15:hotspot
content/03.p53.md:15:tumorigenesis
content/03.p53.md:15:tumorigenesis
content/03.p53.md:19:BRAF
content/03.p53.md:19:Differentially
content/03.p53.md:19:Tumorigenesis
content/03.p53.md:21:adenovirus
content/03.p53.md:21:BRAF
content/03.p53.md:21:BRAF
content/03.p53.md:21:Cre
content/03.p53.md:21:Cre
content/03.p53.md:21:Cre
content/03.p53.md:21:Dankort
content/03.p53.md:21:heterozygosity
content/03.p53.md:21:heterozygous
content/03.p53.md:21:LOH
content/03.p53.md:21:pfu
content/03.p53.md:21:pneumocytes
content/03.p53.md:21:recombinase
content/03.p53.md:21:Spc
content/03.p53.md:21:surfactant
content/03.p53.md:21:tumorigenic
content/03.p53.md:23:homozygous
content/03.p53.md:26:Dedifferentiation
content/03.p53.md:27:dedifferentiated
content/03.p53.md:27:dedifferentiation
content/03.p53.md:27:dedifferentiation
content/03.p53.md:27:dedifferentiation
content/03.p53.md:27:flfl
content/03.p53.md:27:IHC
content/03.p53.md:27:LUAD
content/03.p53.md:27:LUADs
content/03.p53.md:27:SPC
content/03.p53.md:27:SPC
content/03.p53.md:27:transcriptional
content/03.p53.md:29:ARF
content/03.p53.md:29:ARF
content/03.p53.md:29:ARF
content/03.p53.md:29:atypia
content/03.p53.md:29:BRAF
content/03.p53.md:29:heterozygous
content/03.p53.md:29:homozygous
content/03.p53.md:29:homozygous
content/03.p53.md:29:homozygous
content/03.p53.md:29:homozygous
content/03.p53.md:29:IHC
content/03.p53.md:29:immunofluorescence
content/03.p53.md:29:Immunohistochemistry
content/03.p53.md:29:immunostaining
content/03.p53.md:29:phospho
content/03.p53.md:29:transcriptional
content/03.p53.md:31:BRAF
content/03.p53.md:31:MEK
content/03.p53.md:32:BRAF
content/03.p53.md:32:BRAF
content/03.p53.md:32:BRAF
content/03.p53.md:32:BRAF
content/03.p53.md:32:BRAFi
content/03.p53.md:32:chemotherapies
content/03.p53.md:32:Cre
content/03.p53.md:32:dabrafenib
content/03.p53.md:32:dabrafenib
content/03.p53.md:32:dabrafenib
content/03.p53.md:32:Dabrafenib
content/03.p53.md:32:flfl
content/03.p53.md:32:homologue
content/03.p53.md:32:hotspot
content/03.p53.md:32:lentivirus
content/03.p53.md:32:MAPK
content/03.p53.md:32:MEK
content/03.p53.md:32:MEKi
content/03.p53.md:32:missense
content/03.p53.md:32:phosphorylated
content/03.p53.md:32:proliferative
content/03.p53.md:32:Spc
content/03.p53.md:32:trametinib
content/03.p53.md:32:trametinib
content/03.p53.md:32:Trametinib
content/03.p53.md:35:BRAF
content/03.p53.md:35:transcriptome
content/03.p53.md:36:dedifferentiation
content/03.p53.md:36:mesenchymal
content/03.p53.md:36:MYC
content/03.p53.md:36:phenotypes
content/03.p53.md:36:transcriptional
content/03.p53.md:36:transcriptional
content/03.p53.md:36:transcriptomic
content/03.p53.md:36:upregulated
content/03.p53.md:39:PDGFRA
content/03.p53.md:40:PDGFR
content/03.p53.md:40:stimuliation
content/03.p53.md:47:BRAF
content/03.p53.md:47:BRAF
content/03.p53.md:47:Cre
content/03.p53.md:47:Cre
content/03.p53.md:47:Cre
content/03.p53.md:47:Heterozygous
content/03.p53.md:47:homozygous
content/03.p53.md:47:Hotspot
content/03.p53.md:47:Recombinase
content/03.p53.md:47:tumorigenesis
content/03.p53.md:47:wildtype
content/03.p53.md:49:ARF
content/03.p53.md:49:ARF
content/03.p53.md:49:Colocalization
content/03.p53.md:49:dedifferentiation
content/03.p53.md:49:IHC
content/03.p53.md:49:Missense
content/03.p53.md:49:SPC
content/03.p53.md:52:BRAFi
content/03.p53.md:52:BRAFi
content/03.p53.md:52:BRAFi
content/03.p53.md:52:CytotoxRed
content/03.p53.md:52:dabrafenib
content/03.p53.md:52:dabrafenib
content/03.p53.md:52:dabrafenib
content/03.p53.md:52:dabrafenib
content/03.p53.md:52:Ectopic
content/03.p53.md:52:GEMMs
content/03.p53.md:52:Immunoblotting
content/03.p53.md:52:MEKi
content/03.p53.md:52:MEKi
content/03.p53.md:52:phospho
content/03.p53.md:52:timecourse
content/03.p53.md:52:trametinib
content/03.p53.md:52:trametinib
content/03.p53.md:52:trametinib
content/03.p53.md:52:trametinib
content/03.p53.md:52:vitro
content/03.p53.md:52:vitro
content/03.p53.md:55:differentially
content/03.p53.md:55:GSEA
content/03.p53.md:55:transcriptome
content/03.p53.md:55:Upregulated
content/03.p53.md:79:adenocarcinomas
content/03.p53.md:79:BRAF
content/03.p53.md:79:Cre
content/03.p53.md:79:Cre
content/03.p53.md:79:dedifferentiation
content/03.p53.md:79:hotspot
content/03.p53.md:79:leukemias
content/03.p53.md:79:missense
content/03.p53.md:79:missense
content/03.p53.md:79:wildtype
content/03.p53.md:79:wildtype
content/03.p53.md:79:wildtype
content/03.p53.md:81:BRAF
content/03.p53.md:81:BRAF
content/03.p53.md:81:dabrafenib
content/03.p53.md:81:heterozygosity
content/03.p53.md:81:missense
content/03.p53.md:81:trametinib
content/03.p53.md:81:tumorigenesis
content/03.p53.md:81:wildtype
content/03.p53.md:81:wildtype
content/03.p53.md:83:adenocarcinomas
content/03.p53.md:83:ARF
content/03.p53.md:83:ARF
content/03.p53.md:83:ARF
content/03.p53.md:83:ARF
content/03.p53.md:83:ARF
content/03.p53.md:83:ARF
content/03.p53.md:83:BRAF
content/03.p53.md:83:BRAF
content/03.p53.md:83:GOF
content/03.p53.md:83:Hyperactivation
content/03.p53.md:83:MAPK
content/03.p53.md:83:MAPK
content/03.p53.md:83:oncogenic
content/03.p53.md:83:PDAC
content/03.p53.md:83:phospho
content/03.p53.md:85:GOF
content/03.p53.md:85:oligomerization
content/03.p53.md:85:transactivation
content/03.p53.md:85:transcriptional
content/03.p53.md:85:transcriptomes
content/03.p53.md:87:BRAF
content/03.p53.md:87:BRAF
content/03.p53.md:87:BRAF
content/03.p53.md:87:chemotherapies
content/03.p53.md:87:GOF
content/03.p53.md:87:Imatinib
content/03.p53.md:87:immunoblotting
content/03.p53.md:87:ligands
content/03.p53.md:87:LSL
content/03.p53.md:87:MEK
content/03.p53.md:87:PDGF
content/03.p53.md:87:PDGFR
content/03.p53.md:87:PDGFR
content/03.p53.md:87:phenotypes
content/03.p53.md:87:transcriptional
content/03.p53.md:89:dabrafenib
content/03.p53.md:89:dedifferentiation
content/03.p53.md:89:pre
content/03.p53.md:89:proliferative
content/03.p53.md:89:trametinib
content/03.p53.md:89:transcriptomes
content/03.p53.md:89:tumorigenic
content/04.singlecell.md:8:alveoli
content/04.singlecell.md:8:alveoli
content/04.singlecell.md:8:alveoli
content/04.singlecell.md:8:cuboidal
content/04.singlecell.md:8:meshwork
content/04.singlecell.md:8:stereotypic
content/04.singlecell.md:8:surfactant
content/04.singlecell.md:10:adenocarcinomas
content/04.singlecell.md:10:alveoli
content/04.singlecell.md:12:GEMM
content/04.singlecell.md:12:GEMMs
content/04.singlecell.md:12:intra
content/04.singlecell.md:12:pre
content/04.singlecell.md:12:transcriptional
content/04.singlecell.md:12:transcriptomes
content/04.singlecell.md:12:tumoral
content/04.singlecell.md:14:adenocarcinomas
content/04.singlecell.md:14:adenocarcinomas
content/04.singlecell.md:14:adenocarcinomas
content/04.singlecell.md:14:adenocarcinomas
content/04.singlecell.md:14:BRAF
content/04.singlecell.md:14:GEMMs
content/04.singlecell.md:14:GEMMs
content/04.singlecell.md:14:GEMMs
content/04.singlecell.md:14:genotype
content/04.singlecell.md:14:transcriptomes
content/04.singlecell.md:14:tumorigenesis
content/04.singlecell.md:18:genotypes
content/04.singlecell.md:19:Pre
content/04.singlecell.md:20:pre
content/04.singlecell.md:27:heatmap
content/04.singlecell.md:28:heatmap
content/04.singlecell.md:28:MAPK
content/04.singlecell.md:35:KRAS
content/04.singlecell.md:36:homogenous
content/04.singlecell.md:38:genotypes
content/04.singlecell.md:40:mesenchymal
content/04.singlecell.md:45:BRAV
content/04.singlecell.md:45:transcriptional
content/04.singlecell.md:45:wildtype
content/04.singlecell.md:47:Differentially
content/05.Methods.md:2:Adeno
content/05.Methods.md:2:Biosafety
content/05.Methods.md:2:Biosafety
content/05.Methods.md:2:BRAF
content/05.Methods.md:2:CRE
content/05.Methods.md:2:genotyping
content/05.Methods.md:2:genotyping
content/05.Methods.md:2:Gigi
content/05.Methods.md:2:Lozano
content/05.Methods.md:2:SPC
content/05.Methods.md:4:amlifying
content/05.Methods.md:4:AMPure
content/05.Methods.md:4:approximetley
content/05.Methods.md:4:barcode
content/05.Methods.md:4:Barcoded
content/05.Methods.md:4:Cre
content/05.Methods.md:4:CRISPR
content/05.Methods.md:4:DMEM
content/05.Methods.md:4:FBS
content/05.Methods.md:4:genomic
content/05.Methods.md:4:Genomic
content/05.Methods.md:4:HEK
content/05.Methods.md:4:intratracheal
content/05.Methods.md:4:intubation
content/05.Methods.md:4:lentiiral
content/05.Methods.md:4:lentiviral
content/05.Methods.md:4:lentiviral
content/05.Methods.md:4:Lentiviral
content/05.Methods.md:4:Lentivirus
content/05.Methods.md:4:LSL
content/05.Methods.md:4:ofmale
content/05.Methods.md:4:PCR
content/05.Methods.md:4:proteinase
content/05.Methods.md:4:Qubit
content/05.Methods.md:4:sgRNA
content/05.Methods.md:4:Suquencing
content/05.Methods.md:4:titered
content/05.Methods.md:4:Winslow
content/05.Methods.md:4:Winslow
content/05.Methods.md:6:BRAF
content/05.Methods.md:6:Collagenase
content/05.Methods.md:6:cytometry
content/05.Methods.md:6:dispase
content/05.Methods.md:6:DMEM
content/05.Methods.md:6:elastase
content/05.Methods.md:6:lysis
content/05.Methods.md:6:passaged
content/05.Methods.md:6:resuspended
content/05.Methods.md:6:resuspended
content/05.Methods.md:6:RPMI
content/05.Methods.md:6:stromal
content/05.Methods.md:6:tdTomato
content/05.Methods.md:6:trypsinization
content/05.Methods.md:8:DMEM
content/05.Methods.md:8:FBS
content/05.Methods.md:8:HCC
content/05.Methods.md:8:mycoplasma
content/05.Methods.md:10:BCA
content/05.Methods.md:10:clX
content/05.Methods.md:10:Immunoblotting
content/05.Methods.md:10:Licor
content/05.Methods.md:10:lysate
content/05.Methods.md:10:lysed
content/05.Methods.md:10:microgram
content/05.Methods.md:10:phosphatase
content/05.Methods.md:10:protease
content/05.Methods.md:10:PVDF
content/05.Methods.md:10:RIPA
content/05.Methods.md:10:SDS
content/05.Methods.md:10:supernatant
content/05.Methods.md:10:tris
content/05.Methods.md:12:fastq
content/05.Methods.md:12:FastQC
content/05.Methods.md:12:FeatureCounts
content/05.Methods.md:12:Galazy
content/05.Methods.md:12:Illumina
content/05.Methods.md:12:mRNA
content/05.Methods.md:12:MultiQC
content/05.Methods.md:12:Qiagen
content/05.Methods.md:12:TruSeq
content/05.Methods.md:12:UDI
content/05.Methods.md:14:ARF
content/05.Methods.md:14:Immunofluoresence
content/05.Methods.md:14:Immunohistochemistry
content/05.Methods.md:14:Immunohistochemistry
content/05.Methods.md:14:phospho
content/05.Methods.md:14:SPC
content/05.Methods.md:17:Caseviewer
content/05.Methods.md:17:eosin
content/05.Methods.md:17:Hematoxylin
content/05.Methods.md:17:Histech
content/05.Methods.md:17:Histech
content/05.Methods.md:17:Histech
content/05.Methods.md:17:IHC
content/05.Methods.md:17:Pannoramic
content/05.Methods.md:17:QuantCenter
content/05.Methods.md:17:QuantCenter
content/05.Methods.md:17:Thermo
content/05.Methods.md:21:Actin
content/05.Methods.md:21:wb
content/05.Methods.md:22:IHC
content/05.Methods.md:22:Phospho
content/05.Methods.md:22:wb
content/05.Methods.md:23:wb
content/05.Methods.md:24:IHC
content/05.Methods.md:24:Leica
content/05.Methods.md:24:wb
content/05.Methods.md:25:Abcam
content/05.Methods.md:25:IHC
content/05.Methods.md:26:IHC
content/05.Methods.md:26:Millipore
content/05.Methods.md:26:SPC
content/05.Methods.md:27:IHC
content/05.Methods.md:28:ARF
content/05.Methods.md:28:Sherr
content/05.Methods.md:29:ATCC
content/05.Methods.md:29:CRL
content/05.Methods.md:30:Bivona
content/05.Methods.md:30:HCC
content/05.Methods.md:31:Addgene
content/05.Methods.md:31:Recombinant
content/05.Methods.md:32:Addgene
content/05.Methods.md:32:Recombinant
content/05.Methods.md:33:Addgene
content/05.Methods.md:33:Recombinant
content/05.Methods.md:34:dabrafenib
content/05.Methods.md:34:Selleck
content/05.Methods.md:35:Plexxikon
content/05.Methods.md:36:Selleck
content/05.Methods.md:36:trametinib
content/05.Methods.md:37:Collagenase
content/05.Methods.md:37:Thermo
content/05.Methods.md:38:Dispase
content/05.Methods.md:39:Biochem
content/05.Methods.md:39:Elastase
content/05.Methods.md:39:Worthington
content/05.Methods.md:40:Cre
content/05.Methods.md:40:VVC
content/06.future.md:4:BRAF
content/06.future.md:5:BRAF
content/06.future.md:5:heterogenity
content/06.future.md:5:scRNA
content/06.future.md:5:supressor
content/06.future.md:5:tumorigenesis
content/06.future.md:6:heterogenity
content/06.future.md:6:MAPK
content/06.future.md:6:supression
content/06.future.md:10:immuno
